Sonographic imaging is arguably the most important technology developed in the past three decades for aiding the clinical management of pregnancy. Usage has increased rapidly due to the refinement of the technology and widespread development of skills for performing and interpreting sonography. Indications are broad and include the categories of diagnosis, assessment of fetal wellbeing, and therapies aided by sonographic guidance. Most pregnant women are enthusiastic about undergoing sonography and welcome the opportunity to see the fetus and obtain keepsake pictures. This has also contributed to the high-use rate of sonography in pregnancy, even in those at minimal increased risk for adverse outcomes.
Because of the need to increase the costeffectiveness of medical care, medical technologies have come under increased scrutiny to assess whether use improves outcome. Little research has been performed to determine whether sonography for specific indications makes a difference in re-lated outcomes of pregnancy. Routine sonography, however, has generated considerable interest. It is intuitive that there may be benefits to routine use of sonography in pregnancy, even for those not at risk. For example, even a low-risk pregnancy may have erroneous dating caused by delayed ovulation or a fetal anomaly not predicted by historical risk. However, because sonography requires an expensive infrastructure, including both equipment and trained observers, it is important to establish whether routine use of sonography in pregnancies not at risk will improve outcome. In addition, there is the possibility that the application of this technology may incur risk. For example, there is the physical risk of the sonogram and also the potential for increased use of resources as a result of falsepositive diagnoses or diagnoses with outcomes that are not altered by diagnosis. This literature review addresses the evidence for the risks and benefits of routine screening sonography in pregnancy.
Requirements for a Screening Program
Screening for any condition or disease has considerable implications for the use of health resources, especially if applied universally. Screening without demonstrable benefit wastes resources and makes no difference in the health of a population. Essential requirements must be met before establishing a screening program.
BENEFITS OF A SCREENING TEST
An essential requirement of screening is using a test, applied either universally or to a target population, that may ascertain or treat disease in an early, asymptomatic period. For example, screening for cervical cancer by Pap smear fulfills this requirement. A pregnancy with incorrect dating may fulfill this criterion in principle if, for example, correction of dates were to result in administering corticosteroids for fetal lung maturity or avoiding induction for postterm status, which would improve maternal and fetal health outcome.
OUTCOMES AFFECTED BY A SCREENING TEST
The outcome affected by a screening program should be an important health outcome rather than an intermediate outcome. Thus, a screening pro-gram used to ascertain asymptomatic hypertension may be justified based on a reduced rate of stroke or myocardial infarction in the screened population but not on the degree to which blood pressure is reduced in treated individuals. For sonography, examples of intermediate outcomes would include ascertaining an anomaly, correcting gestational age, and suspecting intrauterine growth restriction, whereas health outcomes would include perinatal mortality, neonatal morbidity, and cesarean delivery rate.
In the United States, the excellent care provided to women is the usual care. For example, because there is a high rate of labor induction in the United States, the prevalence of perinatal morbidity from postterm pregnancy may be so low that differences cannot be ascertained between care provided as the result of sonography screening and usual care.
SUFFICIENT CASES
Another important requirement for establishing a screening program is that the ascertained condition be prevalent enough to yield sufficient cases and incur substantial morbidity and mortality. Screening for a rare disease or condition is unlikely to result in improved health of a population unless there is substantial morbidity or burden of suffering incurred. For example, screening for breast cancer results in a reduction of morbidity and mortality from this common malignancy, but tests of routine screening for ovarian cancer have not demonstrated the same benefit because of the relative rarity of the disease in the screened population.
AVAILABILITY AND ACCEPTABILITY
Additional requirements for screening programs include a willing population and readily available diagnostic and treatment facilities. Because the desire to undergo sonography in pregnancy is high, these criteria are easily met. However, for some patients who undergo sonographic screening, there may be barriers to obtaining follow-up diagnostic testing or treatment on the basis of geographic disadvantage or financial constraints.
LOW EXPENSE AND RELIABILITY
The ideal screening test is inexpensive and readily interpreted. A screening test must be reli-able on an interobserver and intraobserver basis. Finally, a screening test must be valid; therefore, it must test what it intends to test well. The appropriate measures of validity for a screening test are sensitivity and specificity, qualities largely independent of disease prevalence.
Sonography as a Screening Test
A routine sonographic examination during pregnancy represents both a diagnostic and a screening test. It is diagnostic, within the limits of reproducibility, for fetal number, viability, fetal presentation, placental location, amniotic fluid volume, and fetal measurements used to confirm or refute gestational age. In general, the use of a diagnostic test in a screening program is undesirable because diagnostic tests are more expensive and require skill for performance.
The use of sonography to detect fetal anomalies represents the application of a screening test. Screening for fetal anomalies can result in falsenegative and false-positive results. Unlike the ideal screening test, screening for fetal anomalies requires substantial skill and may therefore be subject to an unsatisfactory degree of interobserver variability.
The reliability of sonographic screening has not been established systematically. In the Helsinki Ultrasound Trial, 1 fetal sonography was performed at two sites. The sensitivity of sonographic screening for anomalies was 36% at the nonuniversity site and 76.9% at the university site. The author reported that there was a greater interest in diagnosing anomalies at the university site. A similar disparity was found in the report by Crane et al 2 of the RADIUS trial. In this study, multiple sites were used for fetal screening. The sensitivity was found to be 13% for nontertiary sites and 35% for the tertiary sites. In these two studies, it is unclear whether the observed disparity in detection was attributable to variation in skill or to diagnostic bias. Most recently, Van Dorsten et al 3 reported on fetal screening performed at two sites under the control of their tertiary center personnel, one of which had the capability of targeted imaging. The sensitivity at the two sites was very similar, but there was a substantial difference in sensitivity for detecting anomalies depending on the indication for sonography and the risk for fetal anomaly. The sensitivity was approximately 90% for those with an indication placing the patient at high risk for fetal anomaly. The sensitivity was 48% for those having routine sonography. This strongly suggests the possibility of diagnostic bias (i.e., that someone is more likely to be diagnosed with a condition if there is heightened suspicion for any reason). The extent to which interobserver and intraobserver variability, skill, and biases influence the sensitivity of fetal screening are not known, but there seems to be a substantial effect. This is particularly important because the majority of pregnant women in the United States obtain care in nontertiary settings, and sonography applied universally as a screening procedure would include women without an indication for sonography.
Factors Affecting Sensitivity for Anomalies Screening
Sensitivity is an important component in determining the efficacy of fetal screening for anomalies. Ordinarily, the sensitivity of a screening test is independent of the prevalence of the condition for which screening is performed. However, because sonography is a test requiring skill in both performance and interpretation, the test validity is likely to vary according to the environment in which the examination is performed 4 and the experience of the observer.
Another factor likely to affect reported sensitivity is whether all anomalies are detected. It is generally accepted that 2% to 3% of all infants are born with a major anomaly. Only a portion of these anomalies is amenable to diagnosis by sonography. It has been estimated that only 27% of major malformations are readily detectable by sonography, and even if cardiovascular abnormalities, cleft lip, and clubfoot were easily ascertained, nearly 40% of major malformations would still be undetectable. 5 A third factor that may influence reported sensitivity of sonographic screening for anomalies is the method of calculation. Some fetuses with anomalies have more than one abnormality, but it is important that sensitivity be reported with anomalous fetuses as the denominator, rather than anomalies. Once an abnormality is suspected in a fetus, the indicated targeted imaging is more likely to find other anomalies present.
Finally, the population used for a screening may affect the resultant sensitivity. In the RADIUS study, women were specifically excluded from the trial if they had various risk factors or intended to undergo sonography for any reason (e.g., amniocentesis for maternal age). As discussed previously, one study demonstrated a substantial difference in sensitivity between populations at risk for anomalies versus those without increased risk. 3 There have been numerous reports of sonographic sensitivity in detecting fetal anomalies. Studies that report true-positive results, falsepositive results, total number of fetuses with anomalies born, and sensitivity using fetuses with anomalies as the denominator are different. There is a wide range of reported sensitivities. Calculating the sensitivity for second-trimester examinations ranges from 15% to 74%. 4 This suggests that interobserver variability may be a significant problem, as might be expected from a test that requires skill in performances and interpretation. Whatever the extent to which interobserver variability influences variation in sensitivity, it has implications in a test performed at a large number of sites across the country.
Safety of Sonography
Although there is a theoretical risk of tissue damage caused by sonography, there is no consistent evidence of fetal risk caused by the exposure occurring with diagnostic sonography. The most reassuring data regarding long-term development have been from follow-up evaluations of children whose mothers participated in the Norwegian and Swedish randomized trials. 6 Salvesen et al 7 analyzed school performance, as assessed by the children's teachers, of children ages eight to nine years. There were no differences in various measures between children exposed to sonography on a routine basis versus those who received usual care. At ages eight to nine years, there were no differences in speech or motor development or in behavioral disorders between groups sorted by the presence or absence of actual sonographic exposure. 7 The measures analyzed suggest no obvious disturbances in development several years after in utero sonographic exposure.
Counseling for Sonography as a Screening Test
The uncertainty regarding the sensitivity of sonography as a screening test for anomalies underlines the importance of pretest counseling. Ideally, each unit performing sonographic examinations should know its own sensitivity for ascertaining anomalies. This is unrealistic, however, because low prevalence of anomalies would require collecting information from thousands of patients and carefully examining newborns to obtain a reasonable estimate of sensitivity.
As with all screening tests, patients undergoing sonography, including an anatomic fetal survey, should be provided with the following information: an explanation regarding the difference between a screening test and a diagnostic test, a 2% to 3% baseline rate of major anomalies, the limitations of screening, possible results, and the implications of those results. They should be informed that at least one-third of major anomalies cannot be detected by sonography and that reported sensitivities for ascertaining those that can be detected vary considerably by unit but are likely to be < 50%. For a single second-trimester examination, an even lower sensitivity would be expected. This means that even with a single sonographic examination showing a normal fetus, a woman still has at least a 1% to 2% risk of a major anomaly. The false-negative rate of the test is 1% to 2%.
Pretest counseling is also important because a substantial minority of women in the United States will not terminate a pregnancy for an anomaly, and some women decline screening tests. For these women, a sonogram that raises the possibility of an anomaly may provide unwanted information and uncertainty if further diagnostic evaluation is declined. Because a fetal anatomic survey is part of a basic sonographic examination, this issue may need to be addressed with patients undergoing sonography to ensure respect for their ethical position.
